Skip to main content
Premium Trial:

Request an Annual Quote

Warnex to Distribute DeCode Genetics Tests in Canada

NEW YORK (GenomeWeb News) – Warnex today said that it has signed an agreement to serve as exclusive distributor of 10 of DeCode Genetics' tests in Canada.

Most of the DNA-based tests are for assessing risk of developing certain diseases. The tests will be sold by the Warnex Medical Laboratories division of the Laval, Quebec-based firm.

Among those included under the agreement are tests for assessing the risk of developing prostate cancer, myocardial infarction, atrial fibrillation, breast cancer, type 2 diabetes, and glaucoma. It also includes a test for clopidogrel dosing as well as three panels that address a wide range of cancers, cardiovascular diseases, and the DeCode Complete test, which analyzes risk factors for more than 45 common diseases and traits.

"Our test helps to meet the need for improved risk stratification and patient outcomes, and we believe that this alliance will make these benefits more widely available," DeCode Genetics CEO Kari Stefansson said in a statement.

Financial and other terms of the alliance were not disclosed.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.